Sun Pharmaceuticals , India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday, aided by higher demand for its specialty drugs that are used to treat uncommon medical conditions.

Sun Pharma shares are poised for attention on Tuesday after the company reported a 28% YoY growth in consolidated net profit, reaching Rs 3,040 crore in the second quarter. Revenue from operations rose by 9% YoY to Rs 13,

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat estimates.

Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday, aided by strong sales of its specialty drugs that are used to treat uncommon medical conditions.

Sun Pharmaceutical Industries has reported a notable 28% increase in its consolidated net profit, amounting to Rs 3,040 crore for the September quarter. This rise in profit underscores the company's growth trajectory and strategic commercial agreements to expand its specialty product offerings.

Sun Pharma reported a 28% increase in consolidated net profit for the second quarter ended September, at Rs 3,040 crore, with sales up by 9% to Rs 13,291 crore. The performance was buoyed by robust sales in its main markets,

Sun Pharmaceutical Industries Ltd on Monday reported an 28% year-on-year rise in its consolidated net profit for the fiscal's second quarter ended September (Q2FY24) to ₹3,040.16 crore. The company had reported a profit of ₹23,

Sun Pharmaceutical Industries reported a 28% rise in net profit, reaching Rs 3,040 crore for the September quarter, driven by strong sales in India and the US. Notably, the company expanded its specialty pipeline and is leveraging its cash position to enhance its product lineup.